Abstract

Gynecologic cancers, encompassing ovarian, cervical, uterine, vulvar, and vaginal malignancies, represent a significant health burden globally. Clinical trials are pivotal in advancing therapeutic strategies, improving patient outcomes, and shaping evidence-based practices. This article examines the landscape of clinical trials in gynecologic cancer, highlighting breakthroughs in targeted therapies, immunotherapies, and personalized medicine. We discuss key findings from landmark studies, ongoing trials exploring novel therapeutic agents, and the integration of molecular profiling in treatment selection. Additionally, challenges such as trial accessibility, patient enrollment, and disparities in representation are critically analyzed. By providing a comprehensive overview of past achievements and future directions, this review underscores the critical role of clinical trials in transforming the management of gynecologic cancers.